Overview of Dislep

Property	Description
Active ingredient	Levosulpiride
Form	Tablet, Oral Solution, Solution for Injection
Pharmacological class	Atypical Antipsychotic, Gastrointestinal Prokinetic Agent
General purpose	Helps regulate mood and improve stomach movement
Origin	Synthetic (Substituted Benzamide derivative)

Dislep is the brand name for a prescription pharmaceutical product containing the single active ingredient Levosulpiride. This compound is distinguished by its unique, dual pharmacological classification as both an Atypical Antipsychotic and a potent Gastrointestinal Prokinetic Agent. It belongs to the substituted benzamide neuroleptic class, which is characterized by its influence on the central nervous system.

The medicine acts by balancing neurological and digestive functions. Levosulpiride serves as a selective dopamine D2 receptor antagonist in both the brain and the gut. This selective action regulates gastric motility and accelerates gastric emptying, which is utilized in managing symptoms like persistent upper abdominal discomfort. This supports the drug’s general role: promoting regularity in digestive transit and supporting emotional balance.

Composition and Forms of Levosulpiride

Levosulpiride is a synthetic compound derived from the substituted benzamide chemical class; it is the levorotatory enantiomer of the older, racemic drug Sulpiride. Its status as an isolated enantiomer is significant, as this form is associated with improved pharmacological actions compared to the racemic mixture. As a single active ingredient product (monotherapy), the drug delivers the focused action of Levosulpiride through multiple dosage forms suitable for both oral and parenteral delivery to adults. These preparations include solid tablets, an oral solution (or drops), and a sterile solution for injection/infusion for use in clinical settings, providing essential flexibility in patient care.

What side effects are possible with Dislep?

Possible Side Effects and Safety Information

The safety profile of Dislep (Levosulpiride) is formally documented by regulatory authorities, classifying possible adverse reactions based on their frequency and the body system affected. These classifications establish the officially recognized risks associated with the medicine.

Frequency and System-Organ Classes

The most frequently observed effects relate to the nervous system and endocrine system. Side effects classified as Very Common (affecting at least 1 in 10 people) include weight gain, insomnia, constipation, vertigo, and fatigue. Common effects (affecting at least 1 in 100 people) primarily involve hormonal changes due to elevated prolactin levels, such as menstrual disorders, breast swelling/tenderness, and gynaecomastia (breast enlargement in men).

Classification	Examples of Adverse Reactions
Very Common	Weight gain, Insomnia, Constipation, Vertigo, Fatigue
Common	Drowsiness, Sedation, Menstrual disorders, Gynaecomastia

Serious Adverse Reactions and Safety Constraints

The regulatory labeling explicitly documents the potential for rare but serious adverse reactions. These include the risk of developing Neuroleptic Malignant Syndrome (NMS), which is a life-threatening neurological condition, and severe ventricular arrhythmias (irregular heart rhythms), including torsade de pointes, which can lead to cardiac arrest. The formation of venous thrombi (blood clots) is also documented as a risk.

Safety guidelines establish specific constraints. Use is not indicated in children, and it is generally contraindicated during pregnancy, as there is a risk of neonatal withdrawal symptoms if taken in the last trimester. The medication is also contraindicated in patients with conditions like pheochromocytoma or a history of epilepsy and is restricted in patients with gastrointestinal obstruction or perforation.

Overdose and Emergency Response

Overdose and when to seek help

The following information details the officially documented manifestations and required actions in case of an overdose of Levosulpiride (Dislep), as defined by government regulatory authorities.

Documented Overdose Manifestations

Official labeling describes that taking more than the prescribed dose may present with severe central nervous system (CNS) and motor disturbances. Documented manifestations include tremors, drowsiness, sleep disturbances, and extrapyramidal disorders, such as difficulty and slowness of movement and involuntary muscle movements (dystonia).

Severe Outcomes and Required Actions

The regulatory profile explicitly lists the risk of severe, life-threatening cardiovascular effects. These include alterations in the heartbeat, prolongation of the QT interval, ventricular arrhythmias (such as Torsade de pointes), and cardiac arrest.

Due to these potential severe outcomes, the official regulatory instruction is to notify your doctor immediately or go to the nearest hospital if an overdose is suspected or confirmed. Symptomatic and supportive management is the general standard of care; however, the official labeling does not specify the existence of a specific antidote or mandate specific procedural interventions.

Therapeutic Uses of Dislep

What Dislep Treats: Main Uses and Benefits

The medicine is relevant across domains where additional symptomatic support is needed, including in Gastroenterology and Neuro-psychiatry. It is commonly used to treat conditions characterized by periods of heightened symptoms, such as Functional Dyspepsia, Gastroesophageal Reflux Disease, and Irritable Bowel Syndrome in the digestive tract. It is also applied in situations involving certain distressing symptoms linked to neurological activity, including schizophrenia, depression with prominent physical complaints, acute vertigo, and Burning Mouth Syndrome.

The use of this medicine is intended to help patients cope more steadily with symptom fluctuations. It is applied in clinical settings that involve acute or unstable symptom patterns, aiming to assist with maintaining functional stability when symptoms interfere with routine activities.

“It is relevant for managing symptom clusters that may become intense or disruptive, especially those linked to the upper digestive tract.”

Quick Fact: Supports Episodic Discomfort The treatment supports patients during difficult episodes by easing the overall symptom load associated with persistent upper abdominal fullness, discomfort, nausea, and specific neurological disturbances like vertigo.

Regulatory References

Rwanda FDA Summary of Product Characteristics

Eligibility and Restrictions for Use

Official Eligibility Profile for Dislep (Levosulpiride)

Official regulatory documents define strict population eligibility for Dislep, primarily restricting use to Adults who do not present with specific contraindications.

Eligibility Domain	Status Defined by Regulators
Prolactin-Dependent Tumors	Contraindicated (e.g., prolactinoma, breast cancer) [Source 1.5]
Neurological History	Contraindicated (Epilepsy, history of convulsive states, or current manic states) [Source 1.5]
Gastrointestinal Integrity	Contraindicated (Gastrointestinal bleeding, obstruction, or perforation) [Source 1.5]
Phaeochromocytoma	Contraindicated (adrenal gland tumor) [Source 1.5]
Pregnancy and Lactation	Contraindicated [Source 1.5]

Age-Related and Organ Function Restrictions

Pediatric Use: The medicine is not recommended for children and adolescents under 18 years due to insufficient clinical data [Source 1.1].
Older Adults (Geriatric): Use requires caution [Source 1.1].
Renal/Hepatic Impairment: Use requires caution and precautions must be taken for patients with a history of renal or hepatic impairment [Source 1.2]. Dose reduction is advised for kidney failure [Source 1.1].
Cardiovascular Conditions: Cautious use is advised for patients with cardiovascular disorders or a family history of QT prolongation [Source 1.2].

These constraints establish that patients outside the adult population or with the listed contraindications are not eligible for Levosulpiride under standard official labeling.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information for Levosulpiride (Dislep) documents several pharmacokinetic and pharmacodynamic interaction patterns that impose restrictions on co-administration.

Pharmacodynamic Interactions are characterized by additive effects, notably with CNS Depressants (including alcohol, sedatives, or hypnotics), which increase the risk of additive sedative effects and enhanced CNS depression. Strong restrictions apply to combinations that affect cardiac function: co-administration with Drugs that prolong the QT interval (e.g., cisapride) and Drugs that cause electrolyte abnormalities (e.g., diuretics) significantly increases the documented risk of cardiac arrhythmias. Furthermore, co-administration with Levodopa results in Pharmacodynamic Antagonism, reducing the clinical efficacy of Levosulpiride.

Pharmacokinetic Interactions primarily involve absorption interference. Agents such as Sucralfate and Antacids containing aluminium or magnesium reduce the systemic bioavailability of Levosulpiride. To counteract this, regulatory documents specify a timing-based interaction rule: Levosulpiride must be administered at least two hours after ingesting these compounds. A population-specific constraint requires caution when combining Levosulpiride with Monoamine Oxidase Inhibitors (MAOIs) in patients with essential hypertension due to a potential hypertensive risk.

Mechanism of Action

Modulating Dopamine Signaling in the Nervous System

This drug acts by selectively blocking (antagonizing) Dopamine D2 receptors in the central nervous system (CNS). This antagonism modifies the flow of information through dopaminergic pathways, resulting in an adjustment of neurochemical signaling within specific brain regions. The mechanism focuses on influencing pathways that regulate neurochemical activity.

Enhancing Movement in the Digestive Tract

The drug exerts a separate action on the peripheral nervous system within the gastrointestinal tract. It blocks peripheral D2 receptors and simultaneously activates (agonizes) Serotonin 5-HT4 receptors in the gut wall. This dual mechanism leads to an increased release of acetylcholine. Acetylcholine is a neurotransmitter that increases the force and coordination of smooth muscle contractions, resulting in enhanced propulsion of contents through the gastrointestinal tract (a prokinetic effect).

Dosage and Administration Information

How to Use Dislep: Administration Guidelines

The administration of Levosulpiride (Dislep) follows specific guidelines regarding route, dose, and temporal pattern. The medicine is used via the oral route (as a standard tablet, sustained release tablet, or solution) or the parenteral route (intramuscular or slow intravenous injection).

Dosing Schedules and Timing

Oral dosing follows two primary regimens: the standard 25 mg tablet is typically administered three times daily (TID), while the 75 mg Sustained Release (SR) tablet is taken once daily (OD). Parenteral administration, performed by an authorized health professional, involves a dose of 25 mg, two or three times a day. For the standard tablet, administration is typically recommended at least 20 minutes before meals. All tablets must be swallowed whole with water and must not be crushed, chewed, or broken to maintain the integrity of the formulation.

Course Duration and Adjustments

Use is structured into intermittent courses, beginning with parenteral administration until symptoms improve, followed by an oral course often lasting 10 to 15 days. A mandatory interruption period of at least 8 to 10 days is observed between repeated cycles of oral therapy. Clinical guidelines suggest that dose reduction or adjustment is appropriate for older adults, while the medication is not indicated for the pediatric population due to limited experience. If a dose is missed, it is generally taken as soon as remembered, but the missed dose is skipped if it is almost time for the next scheduled dose.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Dislep

Evidence for Use in Functional Dyspepsia

Research examining Levosulpiride's association with changes in common symptoms and motility markers includes Randomized Controlled Trials (RCTs), double-blind studies, and systematic reviews. These studies primarily focused on adults experiencing chronic or recurrent upper abdominal discomfort, particularly the symptoms associated with the dysmotility-like subtype. Researchers studied outcomes related to physical discomfort, such as changes in overall symptom scores, postprandial fullness, and bloating.

Controlled trials monitored how symptoms evolved in the observed populations over short-term to intermediate time intervals. Findings describe patterns observed in the studies where levosulpiride groups showed measured changes in symptom scores compared to those receiving placebo. Studies also monitored physiological outcomes by examining whether the medicine was associated with a measured change in the time it took for food to move through the stomach. What remains uncertain is the durability of the response; the core studies focused mainly on short-term outcomes, meaning the long-term effects are not fully established.

Evidence for Use in Specialized Gastrointestinal Conditions

Research has also explored the study of Levosulpiride in specialized gastrointestinal contexts, notably in patients with diabetic gastroparesis. Researchers focused on outcomes related to systemic or functional imbalance, such as patient-reported outcomes describing perceived discomfort. Studies monitored objective physiological markers, with research examining whether the drug was associated with a measured reduction in the time it took for solid food to empty from the stomach. Some research noted that the changes measured in gastric emptying time did not always align with the way patients reported their own symptom changes.

Research on Neurological and Vestibular Uses

Levosulpiride was also studied for its use in conditions involving acute neurological and vestibular disturbances, such as acute vertigo. These studies monitored outcomes describing episodic or acute changes, using subjective scales to assess the rate of symptomatic change. While research describes some patterns of initial symptomatic change in some populations, the certainty remains low due to modest sample sizes in dedicated studies for this use.

What is Still Uncertain About Dislep Research

Scientific summaries and systematic reviews note several key limitations and uncertainties in the broader evidence base. Evidence quality varies across studies, with some reviews noting that the sample sizes were modest or the studies had methodological limitations. One critical gap is the limited information for long-term outcomes and the potential variability in response across different ethnic groups. The results apply only to the populations studied and the specific conditions under which the trials were conducted.

Frequently Asked Questions (FAQ)

Common questions about Dislep (FAQ)

Q: What happens if I miss taking Dislep at the usual time?

A: Official administration guidelines provide instructions regarding how to handle a missed dose. The missed dose is described as being taken as soon as it is remembered. However, if it is already close to the time for the next scheduled dose, the regulatory instruction indicates that the missed dose is omitted.

Q: Can Dislep cause problems with driving or operating machinery?

A: Regulatory documents advise that this medicine may cause effects such as drowsiness or sedation, particularly at higher doses. Because of this, official product information includes a safety warning for patients regarding the operation of machinery or driving.

Q: What is the potential for withdrawal symptoms if Dislep is stopped?

A: Clinical summaries of the evidence base related to levosulpiride have addressed the potential for drug dependence and withdrawal. These summaries indicate that clinical findings do not point toward a risk of an adult withdrawal syndrome.

Q: Why is regular monitoring important while taking Dislep?

A: Regular patient monitoring is advised by regulatory documents due to the documented potential for serious but rare adverse reactions. These risks include Neuroleptic Malignant Syndrome (NMS) and certain irregular heart rhythms. Monitoring is also recommended to check for potential hormone-related effects.

Q: Can Dislep be used by people with a history of seizures?

A: According to the official eligibility profile, Dislep is contraindicated for individuals with a history of epilepsy or convulsive states. This is because this class of medicine may lower the epileptogenic threshold, which is the point at which a seizure might occur.

Q: Can Dislep be used for people with a history of drug dependence?

A: Regulatory summaries that review the pharmacological properties of levosulpiride have addressed the issue of dependence. These summaries indicate that clinical evidence does not point toward a risk of dependence or tolerance with this active ingredient.

Q: How long can a person expect to take Dislep?

A: Regulatory guidance specifies that the medicine is typically prescribed for defined courses, often lasting 4 weeks, or in some cases up to 8 weeks. The total duration of treatment depends on the specific condition being addressed.

Q: Is Dislep considered a treatment for anxiety or stress?

A: Due to its mechanism of action on the central nervous system, Levosulpiride is classified as an atypical antipsychotic. In some regulatory jurisdictions, it is described as being used in the management of certain anxiety disorders and depression due to its influence on neurological balance.

Q: Is alcohol consumption completely forbidden while using Dislep?

A: The combination of this medicine with alcohol is restricted due to a documented interaction. Alcohol may increase the risk of enhanced central nervous system (CNS) depression and cause additive sedative effects.

Q: How do researchers describe the main effects of Dislep?

A: Researchers and regulatory bodies classify Levosulpiride based on its dual actions as an atypical antipsychotic and a potent gastrointestinal prokinetic agent. This dual classification reflects its documented influence on both neurological balance and digestive movement.

Q: How is the medication Dislep eliminated from the body?

A: Pharmacokinetic data from regulatory monographs describe how the body processes the medicine. The active ingredient is primarily excreted as the unchanged drug, with the elimination process chiefly occurring through the renal route (the kidneys).

Q: Do I need any special tests before starting Dislep?

A: Regulatory guidelines advise on monitoring certain factors that could increase the risk of serious irregular heart rhythms before treatment begins. Regulatory guidelines detail the need to monitor certain conditions, such as low heart rate (bradycardia) or electrolyte imbalances, due to specific risks.

Q: Why is it important to tell the doctor about all other medications before starting Dislep?

A: Disclosing all medications is important because Levosulpiride has documented interactions with several drug classes. This prevents serious health risks that could arise from interactions, such as increased sedative effects, potential irregular heart rhythms, or reduced effectiveness of Dislep itself.

Q: Does Dislep have any known effects on fertility?

A: Official safety documents include information from studies related to the medicine’s potential effects. Studies in animals observed a decrease in fertility, which was linked to the pharmacological effects of the drug related to prolactin.

Q: What specific type of digestive issues can Dislep address?

A: Official product information describes the medicine’s use in the management of symptoms associated with difficulty in stomach emptying and movement. This may include symptoms such as persistent pain, heartburn, feelings of stomach swelling and tension, flatulence, and belching.

Q: Is Dislep used internationally for different purposes than in the US/UK?

A: Yes, regulatory and prescribing information in various countries describes Levosulpiride’s use in both gastrointestinal conditions (like dyspepsia) and certain psychiatric conditions. This includes uses for schizophrenia, depression, and anxiety disorders, reflecting its dual-action classification.

Q: How does Dislep influence mood or emotional state?

A: The drug is described as supporting emotional balance due to its action as a dopamine D2 receptor antagonist in the central nervous system (CNS). Its influence on these neurotransmitter pathways is the basis for its use in psychiatric contexts.

How should Dislep be stored and disposed of?

How to Store and Dispose of Dislep?

The official label mandates specific conditions to maintain the stability of Levosulpiride (Dislep) and ensure safe handling.

Official Storage Requirements

Storage Factor	Regulatory Requirement
Temperature	Store below 30 C (do not exceed 30 C).
Protection	Keep in the original package to protect the medicine from moisture.
Safety	Keep this medicine out of the sight and reach of children.
Stability	The shelf-life is typically 3 years when stored correctly.

Disposal Instructions

Unused or expired medicine must be discarded according to established protocols to protect the environment. Regulatory requirements explicitly state that the product must not be thrown away via wastewater or household waste. All disposal must be done according to local requirements via dedicated pharmaceutical collection programs.

Dislep